



UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

DIVISION OF  
CORPORATION FINANCE

February 20, 2024

Francis Knuettel II  
Interim Chief Executive Officer  
Chromocell Therapeutics Corporation  
4400 Route 9 South, Suite 1000  
Freehold, NJ 07728

**Re: Chromocell Therapeutics Corporation  
Amendment No. 13 to Registration Statement on Form S-1  
Exhibit No. 10.14  
Filed February 14, 2024  
File No. 333-269188**

Dear Francis Knuettel II:

We have concluded our assessment of your redacted exhibit for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences

cc: David Danovitch, Esq.